Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.

by: KN Lazaridis, GJ Gores, KD Lindor

J Hepatol, Vol. 35, No. 1. (July 2001), pp. 134-146.

View FullText article

Pubmed, Hubmed

Reviews [Write a review of this article]

There are no reviews of this article

Find related articles from these CiteULike users

wilvc

Find related articles with these CiteULike tags

Abstract

UDCA exerts its beneficial effect in liver diseases through a diverse, probably, complementary array of mechanisms. The clinical use and efficacy of UDCA in PBC have been evident. UDCA may also have a place in the management of PSC, ICP, cystic fibrosis, PFIC and GVHD involving the liver, although, more studies are needed to further determine its therapeutic potential in these diseases and in other hepatobiliary disorders such as liver allograft rejection, drug and TPN-induced cholestasis, NASH, and alcoholic liver disease.

@article{citeulike:2195431, abstract = {UDCA exerts its beneficial effect in liver diseases through a diverse, probably, complementary array of mechanisms. The clinical use and efficacy of UDCA in PBC have been evident. UDCA may also have a place in the management of PSC, ICP, cystic fibrosis, PFIC and GVHD involving the liver, although, more studies are needed to further determine its therapeutic potential in these diseases and in other hepatobiliary disorders such as liver allograft rejection, drug and TPN-induced cholestasis, NASH, and alcoholic liver disease.}, address = {Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 55905, USA.}, author = {Lazaridis, K. N. and Gores, G. J. and Lindor, K. D. }, citeulike-article-id = {2195431}, issn = {0168-8278}, journal = {J Hepatol}, keywords = {gi}, month = {July}, number = {1}, pages = {134--146}, posted-at = {2008-01-04 18:26:33}, priority = {2}, title = {Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.}, url = {http://view.ncbi.nlm.nih.gov/pubmed/11495032}, volume = {35}, year = {2001} }

RIS record

TY - JOUR ID - citeulike:2195431 L3 - citeulike-article-id:2195431 N2 - UDCA exerts its beneficial effect in liver diseases through a diverse, probably, complementary array of mechanisms. The clinical use and efficacy of UDCA in PBC have been evident. UDCA may also have a place in the management of PSC, ICP, cystic fibrosis, PFIC and GVHD involving the liver, although, more studies are needed to further determine its therapeutic potential in these diseases and in other hepatobiliary disorders such as liver allograft rejection, drug and TPN-induced cholestasis, NASH, and alcoholic liver disease. IS - 1 JF - J Hepatol SN - 0168-8278 AD - Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 55905, USA. EP - 146 TI - Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. VL - 35 SP - 134 KW - gi AU - Lazaridis, KN AU - Gores, GJ AU - Lindor, KD PY - 2001/07// UR - http://view.ncbi.nlm.nih.gov/pubmed/11495032 ER -

RIS BibTeX